Cited by 3,421Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsIntraperitoneal and Appendiceal Malignancies

The DOI matches its Crossref record; 303 of the 309 references it cites were found in a registry or an index.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Open access

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., Arnold, D.·2016·Annals of Oncology

DOI 10.1093/annonc/mdw235

Open this paper in CoChat — free account Open PDF

Abstract

Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw235

Cites

303 of 303 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Items 201–303 of 303

Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology
Ogino, S., Lochhead, P. J., Giovannucci, E. L., Meyerhardt, J. A., Fuchs, C. S., & Chan, A. T. (2013) · Oncogene · doi:10.1038/onc.2013.244 · Cited by 140
Randomized multicentre trial of gadoxetic acid-enhanced MRIversusconventional MRI or CT in the staging of colorectal cancer liver metastases
Zech, C. J., Korpraphong, P., Huppertz, A., Denecke, T., Kim, M., Tanomkiat, W., Jonas, E., & Ba-Ssalamah, A. (2014) · British journal of surgery · doi:10.1002/bjs.9465 · Cited by 138
A combined oncogenic pathway signature of BRAF , KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction
Tian, S., Simon, I., Moreno, V., Roepman, P., Tabernero, J., Snel, M., van't Veer, L., Salazar, R., Bernards, R., & Capella, G. (2013) · Gut · doi:10.1136/gutjnl-2012-302423 · Cited by 128
Self-citation
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial
Tournigand, C., Chibaudel, B., Samson, B., Scheithauer, W., Vernerey, D., Mésange, P., Lledo, G., Viret, F., Ramée, J., Tubiana-Mathieu, N., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00216-8 · Cited by 126
Self-citation
Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
Molinari, F., Martin, V, Saletti, P., De Dosso, S., Spitale, A., Camponovo, A., Bordoni, A., Crippa, S., Mazzucchelli, L., & Frattini, M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604848 · Cited by 122
Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality
Al‐Mulla, F., Going, J. J., Sowden, E., Winter, A., Pickford, I. R., & Birnie, G. D. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199806)185:2 · Cited by 122
PharmGKB summary
Barbarino, J. M., Haidar, C. E., Klein, T. E., & Altman, R. B. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000024 · Cited by 121
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial
Wasan, H. S., Meade, A. M., Adams, R., Wilson, R. H., Pugh, C., Fisher, D. J., Sydes, B., Madi, A., Sizer, B., Lowdell, C. P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70106-8 · Cited by 121
Self-citation
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer
Hecht, J. R., Cohn, A. L., Dakhil, S. R., Saleh, M. N., Piperdi, B., Cline-Burkhardt, M., Tian, Y., & Go, W. Y. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.009 · Cited by 117
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
Ciardiello, F., Normanno, N., Maiello, E., Martinelli, E., Troiani, T., Pisconti, S., Giuliani, F., Barone, C., Cartenì, G., Rachiglio, A. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu230 · Cited by 116
Self-citation
Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group
Moosmann, N., von Weikersthal, L. F., Vehling‐Kaiser, U., Stauch, M. B., Hass, H. G., Dietzfelbinger, H., Oruzio, D. V., Klein, S., Zellmann, K., Decker, T. W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1936 · Cited by 116
Self-citation
Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues
Neumeister, V. M., Anagnostou, V., Siddiqui, S., England, A. M., Zarrella, E., Vassilakopoulou, M., Parisi, F., Kluger, Y., Hicks, D. G., & Rimm, D. L. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs438 · Cited by 115
KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: Biological and clinical implications
Italiano, A., Hostein, I., Soubeyran, I., Fabas, T., Benchimol, D., Evrard, S., Gugenheim, J., Becouarn, Y., Brunet, R., Fonck, M., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0864-z · Cited by 114
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial
Labianca, R., Sobrero, A. F., Isa, L., Cortesi, E., Barni, S., Nicolella, D., Aglietta, M., Lonardi, S., Corsi, D. C., Turci, D., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq580 · Cited by 111
Self-citation
Stereotactic body radiotherapy for liver tumors
Sterzing, F., Brunner, T. B., Ernst, I., Baus, W. W., Greve, B., Herfarth, K. K., & Gückenberger, M. (2014) · Strahlentherapie und Onkologie · doi:10.1007/s00066-014-0714-1 · Cited by 111
Calgb/Swog 80405: Phase III Trial of Irinotecan/5-Fu/Leucovorin (Folfiri) or Oxaliplatin/5-Fu/Leucovorin (Mfolfox6) with Bevacizumab (Bv) or Cetuximab (Cet) for Patients (Pts) with Expanded Ras Analyses Untreated Metastatic Adenocarcinoma of the Colon Or Rectum (Mcrc)
Lenz, H., Niedzwiecki, D., Innocenti, F., Blanke, C. D., Mahony, M. R., O’Neil, B. H., Shaw, J. E., Polite, B. N., Höchster, H. S., Atkins, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu438.13 · Cited by 110
Effect of Prolonged Formalin Fixation on the Immunohistochemical Reactivity of Breast Markers
Arber, D. A. (2002) · Applied immunohistochemistry & molecular morphology · doi:10.1097/00129039-200206000-00015 · Cited by 107
Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer
Moutinho, C., Martínez‐Cardús, A., Santos, C., Navarro-Perez, V., Martinez‐Balibrea, E., Musulén, E., Carmona, F. J., Bianchi, A. S., Cassingena, A., Siena, S., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt322 · Cited by 103
Self-citation
Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin
Elias, D. M., Mariani, A., Cloutier, A., Blot, F., Goèré, D., Dumont, F., Honoré, C., Billard, V., Dartigues, P., & Ducreux, M. P. (2014) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2014.06.006 · Cited by 103
Self-citation
Irinotecan Pharmacogenomics
Marsh, S., & Hoskins, J. M. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.95 · Cited by 103
Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver
Oudejans, J. J., Slebos, R. J. C., Zoetmulder, F. A. N., Mooi, W. J., & Rodenhuis, S. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490613 · Cited by 100
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
Comito, T., Cozzi, L., Clerici, E., Campisi, M. C., Liardo, R. L. E., Navarria, P., Ascolese, A., Tozzi, A., Iftode, C., Rose, F. D., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-619 · Cited by 100
Distinction of Hereditary Nonpolyposis Colorectal Cancer and Sporadic Microsatellite-Unstable Colorectal Cancer through Quantification of MLH1 Methylation by Real-time PCR
Bettstetter, M., Dechant, S., Ruemmele, P., Grabowski, M., Keller, G., Holinski‐Feder, E., Hartmann, A., Hofstaedter, F., & Dietmaier, W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3064 · Cited by 99
Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.
Stintzing, S., Jung, A., Rossius, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Al‐Batran, S., Vehling‐Kaiser, U., Heintges, T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.445 · Cited by 97
Self-citation
Stability of K-ras mutations throughout the natural history of human colorectal cancer
Losi, L., Benhattar, J., & Costa, J. C. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90468-h · Cited by 96
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer
Kemeny, N. E., Capanu, M., D'Angelica, M. I., Jarnagin, W. R., Haviland, D., DeMatteo, R. P., & Fong, Y. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn769 · Cited by 96
Delay to formalin fixation ‘cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry
Portier, B. P., Wang, Z., Downs-Kelly, E. P., Rowe, J. J., Patil, D. T., Lanigan, C., Budd, G. T., Hicks, D. G., Rimm, D. L., & Tubbs, R. R. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.123 · Cited by 95
Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations
Albanese, I., Scibetta, A. G., Migliavacca, M., Russo, A., Bazan, V., Tomasino, R. M., Colomba, P., Tagliavia, M., & La Farina, M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.111 · Cited by 91
Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results.
Ambrosino, G., Polistina, F., Costantin, G., Francescon, P., Guglielmi, R., Zanco, P., Casamassima, F., Febbraro, A., Gerunda, G. E., & Lumachi, F. (2009) · PubMed · Cited by 89
Treatment of Pulmonary Colorectal Metastases by Radiofrequency Ablation
Petre, E. N., Jia, X., Thornton, R. H., Sofocleous, C. T., Alago, W., Kemeny, N. E., & Solomon, S. B. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.07.003 · Cited by 89
Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC).
Ruers, T. J. M., Punt, C. J. A., van Coevorden, F., Pierie, J.-P. E. N., Rinkes, I. H. M. B., Ledermann, J. A., Poston, G. J., Bechstein, W. O., Lentz, M. A., Mauer, M. E. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3501 · Cited by 89
Self-citation
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance
Siravegna, G., & Bardelli, A. (2014) · Genome biology · doi:10.1186/s13059-014-0449-4 · Cited by 88
Self-citation
Combined Ablation and Resection (CARe) as an Effective Parenchymal Sparing Treatment for Extensive Colorectal Liver Metastases
Évrard, S., Poston, G. J., Kissmeyer-Nielsen, P., Diallo, A., Desolneux, G., Brouste, V., Lalet, C., Mortensen, F. V., Stättner, S., Fenwick, S. W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114404 · Cited by 87
Survival Differences in Patients With Metastatic Colorectal Cancer and With Single Site Metastatic Disease at Initial Presentation: Results From South Australian Clinical Registry for Advanced Colorectal Cancer
Khattak, M. A., Martin, H. L., Beeke, C., Price, T. J., Carruthers, S., Kim, S. W., Padbury, R., & Karapetis, C. S. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.06.004 · Cited by 86
Self-citation
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer
Olaussen, K. A., Mountzios, G., & Soria, J. (2007) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32816b5c63 · Cited by 84
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study
Rougier, P. R., Lepille, D., Bennouna, J., Marre, A., Ducreux, M. P., Mignot, L., Hua, A., & Méry-Mignard, D. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf259 · Cited by 84
Self-citation
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
Piessevaux, H. H., Buyse, M. E., Roock, W. D., Prenen, H., Schlichting, M., Cutsem, E. V., & Tejpar, S. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp011 · Cited by 82
Self-citation
High sensitivity of both sequencing and real‐time PCR analysis of KRAS mutations in colorectal cancer tissue
Tol, J., Dijkstra, J. R., Vink-Börger, M. E., Nagtegaal, I. D., Punt, C. J. A., van Krieken, J. H., & Ligtenberg, M. J. L. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00788.x · Cited by 81
Self-citation
Serial FDG–PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy
Hendlisz, A., Golfinopoulos, V., Garcia, C., Covas, A., Emonts, P., Ameye, L., Paesmans, M., Deleporte, A., Machiels, G., Toussaint, E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr554 · Cited by 78
The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer
Spindler, K.-L. G., Pallisgaard, N., Rasmussen, A. A., Lindebjerg, J., Andersen, R. F., Crüger, D. G., & Jakobsen, A. K. M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn712 · Cited by 78
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial
Johnsson, A., Hagman, H., Frödin, J., Berglund, Å., Keldsen, N., Fernebro, E., Sundberg, J., Christensen, R. D., Spindler, K.-L. G., Bergström, D., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt236 · Cited by 77
K‐ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis
Suchy, B., Zietz, C., & Rabes, H. M. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520107 · Cited by 76
Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group
Müller, C., Schulmann, K., Reinacher‐Schick, A., Andre, N., Arnold, D., Tannapfel, A., Arkenau, H., Hahn, S. A., Schmoll, S. H.-J., Porschen, R., et al. (2008) · International Journal of Colorectal Disease · doi:10.1007/s00384-008-0504-2 · Cited by 74
Self-citation
The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays
Babic, A., Loftin, I. R., Stanislaw, S., Wang, M., Miller, R. M., Warren, S. M., Zhang, W., Lau, A., Miller, M., Wu, P., et al. (2010) · Methods · doi:10.1016/j.ymeth.2010.08.012 · Cited by 70
RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group
Wong, N. A. C. S., de Castro, D. G., Salto‐Tellez, M., Butler, R., Díaz‐Cano, S. J., Ilyas, M., Newman, W. G., Shaw, E. C., Tanière, P., & Walsh, S. V. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202467 · Cited by 70
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
Schmiegel, W., Reinacher-Schick, A. C., Arnold, D., Kubicka, S., Freier, W., Dietrich, G., Geißler, M., Hegewisch-Becker, S., Tannapfel, A., Pohl, M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt028 · Cited by 68
Self-citation
Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors
Wada, H., Takai, Y., Nemoto, K., & Yamada, S. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.08.012 · Cited by 63
Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in Fire-3 (Aio Krk-0306) in the Final Ras Evaluable Population
Stintzing, S., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmueller, C., Kahl, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu438.9 · Cited by 62
Self-citation
What to choose as radical local treatment for lung metastases from colo-rectal cancer: Surgery or radiofrequency ablation?
Schlijper, R., Grutters, J. P. C., Houben, R. M. A., Dingemans, A. C., Wildberger, J. E., Raemdonck, D. E. V., Cutsem, E. V., Haustermans, K. M., Lammering, G., Lambin, P., et al. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.004 · Cited by 61
Self-citation
Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas
Zauber, P., Sabbath-Solitare, M., Marotta, S. P., & Bishop, D. T. (2003) · Molecular Pathology · doi:10.1136/mp.56.3.137 · Cited by 60
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
Souglakos, J., Ziras, N., Kakolyris, S., Boukovinas, I., Kentepozidis, N. K., Makrantonakis, P., Xynogalos, S., Christophyllakis, C., Kouroussis, C., Vamvakas, L., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.594 · Cited by 60
Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer.
Guetz, G. D., Mariani, P., Cucherousset, J., Bennamoun, M., Lagorce, C., Sastre‐Garau, X., Toumelin, P. L., Uzzan, B., Perret, G. Y., Morère, J., et al. (2007) · PubMed · Cited by 60
CT-Guided Interstitial Brachytherapy of Primary and Secondary Lung Malignancies
Peters, N., Wieners, G., Pech, M., Hengst, S., Rühl, R., Streitparth, F., Hänninen, E. L., Felix, R., Wust, P., & Ricke, J. (2008) · Strahlentherapie und Onkologie · doi:10.1007/s00066-008-1718-5 · Cited by 60
Self-citation
Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma
Haller, D. G., Rothenberg, M. L., Wong, A. O., Koralewski, P., Miller, W. H., Bodoky, G., Habboubi, N., Garay, C. A., & Olivatto, L. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1249 · Cited by 57
Self-citation
Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk
Kabbinavar, F. F., Irl, C., Zurlo, A., & Hurwitz, H. I. (2008) · Oncology · doi:10.1159/000163850 · Cited by 56
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Lièvre, A., Samalin, E., Mitry, E., Assénat, E., Gestin-Boyer, C., Lepère, C., Bachet, J., Portales, F., Vaillant, J.-N., Ychou, M., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-347 · Cited by 56
Rapid Two-Temperature Formalin Fixation
Chafin, D. R., Theiss, A. P., Roberts, E. A., Borlee, G. I., Otter, M., & Baird, G. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054138 · Cited by 53
Outcomes of Single Fraction Stereotactic Ablative Radiotherapy for Lung Metastases
Filippi, A. R., Badellino, S., Guarneri, A., Levis, M., Botticella, A., Mantovani, C., Ragona, R., Racca, P., Buffoni, L., Novello, S., et al. (2013) · Technology in Cancer Research & Treatment · doi:10.7785/tcrt.2012.500355 · Cited by 52
Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.
Siena, S., Bianchi, A. S., Lonardi, S., Trusolino, L., Martino, C., Bencardino, K. B., Leone, F., Zagonel, V., Valtorta, E., Torri, V., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3508 · Cited by 51
Self-citation
A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases
Fumagalli, I., Bibault, J., Dewas, S., Kramar, A., Mirabel, X., Prévost, B., Lacornerie, T., Jerraya, H., & Lartigau, E. F. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-164 · Cited by 50
Colorectal cancer patients with oligometastatic liver disease: what is the optimal approach?
Weiser, M. R., Jarnagin, W. R., & Saltz, L. B. (2013) · PubMed · Cited by 50
Decision-making in Colorectal Cancer Tumor Board meetings: Results of a prospective observational assessment
Shah, S., Arora, S., Atkin, G. K., Glynne‐Jones, R., Mathur, P., Darzi, A. W., & Sevdalis, N. (2014) · Surgical Endoscopy · doi:10.1007/s00464-014-3545-3 · Cited by 48
Controversies in the oncosurgical management of liver limited stage IV colorectal cancer
Jones, R. P., Stättner, S., Sutton, P. A., Dunne, D. F. J., McWhirter, D., Fenwick, S. W., Malik, H. M. A., & Poston, G. J. (2014) · Surgical Oncology · doi:10.1016/j.suronc.2014.02.002 · Cited by 48
Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy.
Petersen, R. K., Hess, S., Alavi, A. A., & Høilund‐Carlsen, P. F. (2014) · Europe PMC (PubMed Central) · Cited by 46
Efficacy and Toxicity of Hepatic Intra‐Arterial Drug‐Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan‐Refractory Unresectable Colorectal Liver Metastases
Bhutiani, N., Akinwande, O., & Martin, R. C. G. (2015) · World Journal of Surgery · doi:10.1007/s00268-015-3386-9 · Cited by 44
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours
Aung, K. L., R. E. Board, Ellison, G., Donald, E. L., Ward, T. H., Clack, G., Ranson, M., Hughes, A. M., Newman, W. G., & Dive, C. (2010) · The HUGO Journal · doi:10.1007/s11568-011-9149-2 · Cited by 41
Detection of KRAS Mutations in Colorectal Carcinoma Patients with an Integrated PCR/Sequencing and Real-Time PCR Approach
Carotenuto, P., Roma, C., Rachiglio, A. M., Tatangelo, F., Pinto, C., Ciardiello, F., Nappi, O., Iaffaioli, V. R., Botti, G., & Normanno, N. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.86 · Cited by 41
Self-citation
External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer
Tack, V., Ligtenberg, M. J. L., Tembuyser, L., Normanno, N., Borght, S. V., van Krieken, J. H., & Dequeker, E. M. C. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0382 · Cited by 41
Self-citation
Characterisation of focal liver lesions undetermined at grey-scale US: contrast-enhanced US versus 64-row MDCT and MRI with liver-specific contrast agent
Bartolotta, T. V., Taibbi, A., Midiri, M., Grutta, L. L., Maria, M. D., & Lagalla, R. (2010) · La radiologia medica · doi:10.1007/s11547-010-0506-3 · Cited by 40
Association between deficient mismatch repair system and efficacy to irinotecan‐containing chemotherapy in metastatic colon cancer
Kim, J. E., Hong, Y. S., Ryu, M., Lee, J., Chang, H. M., Lim, S., Kim, J. H., Jang, S. J., Kim, M., Yu, C. S., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02009.x · Cited by 39
Management of Peritoneal Carcinomatosis From Colorectal Cancer
Cotte, E., Passot, G., Mohamed, F., Vaudoyer, D., Gilly, F. N., & Gléhen, O. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181a58d67 · Cited by 39
A Review of Conventional and Drug-Eluting Chemoembolization in the Treatment of Colorectal Liver Metastases: Principles and Proof
Liu, D. M., Thakor, A. S., Baerlocher, M. O., Alshammari, M. T., Lim, H. J., Kos, S., Kennedy, A. S., & Wasan, H. S. (2015) · Future Oncology · doi:10.2217/fon.15.3 · Cited by 36
Self-citation
Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes
Weber, J., Meyer, N., Pencreach, E., Schneider, A., Guérin, É., Neuville, A., Stemmer, C., Brigand, C., Bachellier, P., Rohr, S., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22343 · Cited by 34
Computed Tomography-Guided Interstitial High-Dose-Rate Brachytherapy in the Local Treatment of Primary and Secondary Intrathoracic Malignancies
Tselis, N., Ferentinos, K., Kolotas, C., Schirren, J., Baltas, D., Antonakakis, A., Ackermann, H., & Zamboglou, N. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318208c7a3 · Cited by 34
An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer
Poulin-Costello, M., Azoulay, L., Cutsem, E. V., Peeters, M., Siena, S., & Wolf, M. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0271-z · Cited by 34
Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer.
Douillard, J. (2000) · PubMed · Cited by 34
Self-citation
KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance
Dijkstra, J. R., Heideman, D. A. M., Meijer, G. A., Boers, J., Hart, N. A. ‘., Diebold, J., Hirschmann, A., Höefler, G., Winter, G., Miltenberger-Miltényi, G., et al. (2012) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-012-1356-2 · Cited by 29
Self-citation
Microsatellite instability: a predictive marker in metastatic colorectal cancer?
Guetz, G. D., Uzzan, B., Nicolas, P., Schischmanoff, P. O., & Morère, J. (2009) · Targeted Oncology · doi:10.1007/s11523-008-0103-8 · Cited by 27
Independent Radiological Evaluation of Objective Response Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306)
Heinemann, V., Modest, D. P., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmuller, C. A., Kahl, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu193.30 · Cited by 27
Self-citation
ERCC1-Tailored Chemotherapy in Lung Cancer: The First Prospective Randomized Trial
Soria, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3167 · Cited by 24
FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials
Beretta, G. D., Petrelli, F., Stinco, S., Cabiddu, M., Ghilardi, M., Squadroni, M., Borgonovo, K., & Barni, S. (2013) · Medical Oncology · doi:10.1007/s12032-013-0486-y · Cited by 22
The ERCC1 C118T Polymorphism Predicts Clinical Outcomes of Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Meta-analysis Based on 22 Studies
Qian, Y., Liu, X.-Y., Wu, Q., Song, X., Chen, X., Liu, Y., Pei, D., Shen, L., & Shu, Y. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.19.8383 · Cited by 22
ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas
Orlandi, A., Salvatore, M. D., Bagalá, C., Basso, M., Strippoli, A., Plastino, F., Calegari, M. A., Cassano, A., Astone, A., & Barone, C. A. (2014) · Journal of Cancer · doi:10.7150/jca.10478 · Cited by 21
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
Stein, A., Atanackovic, D., Hildebrandt, B., Stübs, P., Brugger, W., Hapke, G., Steffens, C.-C., Illerhaus, G., Bluemner, E., Stöhlmacher, J., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.299 · Cited by 19
Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
Prenen, H., Geva, Vecchione, L., Tejpar, Piessevaux, H. H., & Cutsem, V. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s41383 · Cited by 19
Cost Estimates and Economic Implications of Expanded RAS Testing in Metastatic Colorectal Cancer
Kircher, S. M., Mohindra, N. A., & Nimeiri, H. S. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0252 · Cited by 18
Shifting Sands: Adapting the Multidisciplinary Team Model to Technological and Organizational Innovations in Cancer Care
Prades, J., & Borràs, J. M. (2014) · Future Oncology · doi:10.2217/fon.14.125 · Cited by 18
Phase Ii Study of First-Line Mfolfox Plus Cetuximab (C) for 8 Cycles Followed By Mfolfox Plus C or Single Agent (S/A) C As Maintenance Therapy in Patients (P) with Metastatic Colorectal Cancer (Mcrc): the Macro-2 Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [Ttd])
Alfonso, P., Benavides, M., Ruiz, A. C. S., Guillén‐Ponce, C., Safont, M. J., Alcaide, J., Gómez, A., Lopez, R., Manzano, J. L., Ureña, M. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu333.3 · Cited by 18
A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G).
Yamazaki, K., Nagase, M., Tamagawa, H., Ueda, S., Tamura, T., Murata, K., Tsuda, T., Baba, E., Tsuda, M., Moriwaki, T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3534 · Cited by 18
Self-citation
Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal metastases.
Adam, R. A., Barroso, E., Laurent, C., Nuzzo, G., Hubert, C., Mentha, G., IJzermans, J. N. M., Capussotti, L., López‐Ben, S., Mirza, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3519 · Cited by 16
Self-citation
A microRNA molecular modeling extension for prediction of colorectal cancer treatment
Li, J., & Mansmann, U. (2015) · BMC Cancer · doi:10.1186/s12885-015-1437-0 · Cited by 13
An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM).
Moulton, C.-A., Levine, M. N., Law, C., Hart, R., Ruo, L., Gu, C., Hendler, A. L., Gulenchyn, K. Y., Haider, M. A., Marcaccio, M. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3520 · Cited by 13
“Watchful waiting” for metastatic colorectal cancer, antediluvian or an option to be considered again?
Price, T. J., Townsend, A. R., Beeke, C., Bishnoi, S. K., Padbury, R., Maddern, G. J., & Karapetis, C. S. (2012) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2011.01458.x · Cited by 12
Self-citation
Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy
Nöpel‐Dünnebacke, S., Schulmann, K., Reinacher‐Schick, A., Porschen, R., Schmiegel, W., Tannapfel, A., & Graeven, U. (2014) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0034-1366781 · Cited by 12
Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics
Sanoff, H. K., & McLeod, H. L. (2008) · Seminars in Colon and Rectal Surgery · doi:10.1053/j.scrs.2008.09.007 · Cited by 12
FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Cremolini, C., Loupakis, F., & Falcone, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1413996 · Cited by 11
Self-citation
Perkutane CT-gesteuerte Hochdosis-Brachytherapie (CT-HDRBT) von primären und metastatischen Lungentumoren in nicht chirurgischen Kandidaten
Collettini, F., Schnapauff, D., Poellinger, A., Denecke, T., Banzer, J., Golenia, M., Wust, P., & Gebauer, B. (2012) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/s-0031-1299101 · Cited by 9
Validating the prognostic relevance of initial change in tumor size using a series of therapeutic regimens for patients with metastatic colorectal cancer (mCRC).
Mansmann, U., Laubender, R. P., Giessen, C. A., Sartorius, U., & Heinemann, V. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.580 · Cited by 9
Self-citation
Improved early prediction of individual prognosis for patients with mCRC: Joint modeling of tumor shrinkage with volume data for PFS and OS.
Mansmann, U., Laubender, R. P., Sartorius, U., Giessen, C. A., Graser, A., & Heinemann, V. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3603 · Cited by 9
Self-citation
FOLFOXIRI/Bevacizumab Versus FOLFIRI/Bevacizumab as First-Line Treatment in Unresectable Metastatic Colorectal Cancer: Results of Phase III Tribe Trial by Gono Group
Cremolini, C., Loupakis, F., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Trenta, P., Tomasello, G., Ronzoni, M., Ciuffreda, L., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt201.26 · Cited by 8
Self-citation
Expression of thymidylate synthase in liver and lung metastases of colorectal cancer and their matched primary tumours.
Öhrling, K., Edler, D., Hallström, M., & Ragnhammar, P. (2008) · PubMed · Cited by 8
2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab)
Cascinu, S., Lonardi, S., Rosati, G., Nasti, G., Zaniboni, A., Romiti, A., Aglietta, M., Bilancia, D., Iaffaioli, V. R., Zagonel, V., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(15)30040-x · Cited by 5
Self-citation
PD-014 First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)
Rivera, F., Karthaus, M., Hecht, J. R., Fasola, G., Canon, J.-L., Koukakis, R., Demonty, G., & Schwartzberg, L. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv234.13 · Cited by 5

Research works printed but not linked: 6

Stintzing, 2013, Analysis of KRAS/NRAS and BRAF mutations in FIRE-3, Eur J Cancer, 49
Venook, 2014, J Clin Oncol, 32
Collettini, 2012, Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates, Rofo, 184, 316
Lenz, 2014, Ann Oncol, 25
Garcia Alfonso, 2014, Ann Oncol, 25
Cascinu, 2015, Eur J Cancer, 51

Sorted by citations

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Self-citation
Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glynne‐Jones, R., Wyrwicz, L. S., Tiret, E., Brown, G. M., Rödel, C. M., Cervantes, A. M. R., & Arnold, D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx224 · Cited by 2,098
Self-citation
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Self-citation
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Farkas, L. M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,737
Self-citation

See all 3,421

Authors: Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W. J. G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T. J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H. J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., & Arnold, D.
Affiliations: Universitat de València (ES)
Hôpital Paul-Brousse (FR)
Ospedale Policlinico San Martino (IT)
Tel Aviv University (IL)
University of Turin (IT)
Northwestern Medicine (US)
Unified Szent István and Szent László Hospital (HU)
University of Campania "Luigi Vanvitelli" (IT)
Institut de Cancérologie de l'Ouest (FR)
Université Paris-Saclay (FR)
University of Pisa (IT)
Mayo Clinic (US)
Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
KU Leuven (BE)
Ludwig-Maximilians-Universität München (DE)
Universidade de São Paulo (BR)
Klinikum Oldenburg (DE)
Ospedale Papa Giovanni XXIII (IT)
Chinese University of Hong Kong (HK)
University of Oxford (GB)
Aichi Cancer Center (JP)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Institute of Cancer Research (GB)
Bank of Cyprus Oncology Center (CY)
University of Ioannina (GR)
Odense University Hospital (DK)
Queen Elizabeth Hospital (AU)
Amsterdam UMC Location University of Amsterdam (NL)
University Hospital Magdeburg (DE)
University Hospital of Geneva (CH)
Institut Català d'Oncologia (ES)
Comprehensive Cancer Center Vienna (AT)
Martin Luther University Halle-Wittenberg (DE)
Vall d'Hebron Hospital Universitari (ES)
Universitair Ziekenhuis Leuven (BE)
Imperial College Healthcare NHS Trust (GB)
National Cancer Center Hospital East (JP)
Hôpital Européen Georges-Pompidou (FR)
ORCID: Cervantes, A.
Adam, R.
Sobrero, A.
Bardelli, A.
Benson, A.
Bodoky, G.
Ciardiello, F.
Douillard, J.-Y.
Ducreux, M.
Falcone, A.
Grothey, A.
Gruenberger, T.
Haustermans, K.
Heinemann, V.
Hoff, P.
Labianca, R.
Ma, B.
Maughan, T.
Muro, K.
Normanno, N.
Oyen, W.J.G.
Papamichael, D.
Pentheroudakis, G.
Pfeiffer, P.
Price, T.J.
Punt, C.
Ricke, J.
Salazar, R.
Schmoll, H.J.
Tabernero, J.
Tejpar, S.
Wasan, H.
Yoshino, T.
Zaanan, A.
Arnold, D.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2016-08
Volume: 27
Issue: 8
Pages: 1386-1422
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdw235
OpenAlex: W2470575266
Cited by: 3,421
References: 309
Citations by year: 2026: 199 · 2025: 236 · 2024: 297 · 2023: 364 · 2022: 481 · 2021: 518 · 2020: 444 · 2019: 365 · 2018: 279 · 2017: 189 · 2016: 39
FWCI: 155.89
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1191 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Lirias (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
Funders: Cancer Research UK (13363)
National Institute for Health and Care Research (11/100/50)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: metastatic colorectal cancer, colorectal cancer, surgical resection of metastases, systemic therapy, multidisciplinary management, treatment decision-making, evidence-based recommendations
MeSH terms: Humans, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Guidelines as Topic, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks